<p>Arcus Biosciences, Inc.（纽约证券交易所代码：RCUS - 获取免费报告）内部人士 Richard Markus 于 12 月 16 日（星期二）出售了 5,052 股该公司的股票。股票的平均售价为 21.88 美元，总价值为 110,537.76 美元。出售后，该内部人士持有 70,141 股公司的股票，价值约为 1,534,685.08 美元。此次交易使其持股减少了 6.72%。该交易已在与证券交易委员会的法律文件中披露，您可以通过此链接访问。</p>
<p>获取 <strong>Arcus Biosciences</strong> 的提醒：</p>
<ul>
<li>从落后者到领导者：小型股正在崛起</li>
</ul>
<p>Richard Markus 最近还进行了以下交易：</p>
<ul>
<li>在 12 月 17 日（星期三），Richard Markus 出售了 4,494 股 Arcus Biosciences 的股票。这些股票的平均售价为 22.16 美元，总价值为 99,587.04 美元。</li>
</ul>
<h2>Arcus Biosciences 股价下跌 1.2%</h2>
<p>在周四的午盘交易中，纽约证券交易所 RCUS 的股票下跌了 0.26 美元，跌至 22.02 美元。该公司的股票交易量为 1,175,874 股，而其平均交易量为 1,200,446 股。Arcus Biosciences, Inc.的股价一年低点为 6.50 美元，一年高点为 26.40 美元。该公司的 50 日简单移动平均线为 20.82 美元，200 日简单移动平均线为 13.98 美元。该公司的债务与股本比率为 0.22，流动比率为 3.65，速动比率为 3.65。该股票的市值为 23.8 亿美元，市盈率为-6.40，贝塔值为 0.75。</p>
<ul>
<li>MarketBeat 周报 – 7/10 - 7/14</li>
</ul>
<p>Arcus Biosciences（纽约证券交易所代码：RCUS - 获取免费报告）最近在 10 月 28 日（星期二）发布了其财报。该公司报告本季度每股收益（EPS）为-1.27 美元，超出市场共识预期的-1.33 美元 0.06 美元。该公司本季度的收入为 2600 万美元，而分析师预期为 1989 万美元。Arcus Biosciences 的净利润率为-136.40%，股本回报率为-68.17%。与去年同期相比，该公司的季度收入下降了 45.8%。在去年同期，该公司每股收益为-1.00 美元。平均而言，卖方分析师预计 Arcus Biosciences, Inc.在当前财年将发布-3.15 的每股收益。</p>
<h2>机构资金流入和流出</h2>
<p>几家机构投资者最近调整了对 RCUS 的持股。Amalgamated Bank 在第三季度将其在 Arcus Biosciences 的持股增加了 3.9%。Amalgamated Bank 目前持有 19,533 股该公司的股票，价值 266,000 美元，此前在上个季度又购买了 736 股。Creative Planning 在第三季度将其在 Arcus Biosciences 的持股增加了 2.7%。Creative Planning 目前持有 29,629 股该公司的股票，价值 403,000 美元，此前在上个季度又购买了 771 股。GAMMA Investing LLC 在第三季度将其在 Arcus Biosciences 的持股增加了 59.1%。GAMMA Investing LLC 目前持有 2,748 股该公司的股票，价值 37,000 美元，此前在此期间又收购了 1,021 股。宾夕法尼亚州公共学校雇员退休系统在第二季度将其在 Arcus Biosciences 的持股增加了 8.0%。宾夕法尼亚州公共学校雇员退休系统目前持有 17,398 股该公司的股票，价值 142,000 美元，此前在上个季度又收购了 1,294 股。最后，Parallel Advisors LLC 在第二季度将其在 Arcus Biosciences 的持股增加了 1.6%。Parallel Advisors LLC 目前持有 88,007 股该公司的股票，价值 716,000 美元，此前在此期间又收购了 1,422 股。92.89% 的股票目前由机构投资者和对冲基金持有。</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>Gilead 通过在 AlloVir 和 Arcus 的投资扩大生物科技足迹</li>
</ul>
<p>几家券商最近对 RCUS 发布了报告。Weiss Ratings 在 10 月 8 日（星期三）的研究报告中重新发布了对 Arcus Biosciences 股票的 “卖出（d-）” 评级。Wall Street Zen 在周日将 Arcus Biosciences 的评级从 “卖出” 上调至 “持有”。Wedbush 在 10 月 29 日（星期三）的研究报告中对 Arcus Biosciences 设定了 35.00 美元的目标价，并给予该股票 “跑赢大盘” 的评级。瑞银集团在周一的研究报告中重新发布了对 Arcus Biosciences 股票的 “买入” 评级。最后，花旗集团在 12 月 12 日（星期五）的研究报告中重申了对 Arcus Biosciences 股票的 “买入” 评级。八位投资分析师对该股票给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat，该股票目前的共识评级为 “适度买入”，共识目标价为 28.89 美元。</p>
<p><strong>获取我们最新的 RCUS 研究报告</strong></p>
<h2>Arcus Biosciences 公司简介</h2>
<p>（获取免费报告）</p>
<p>Arcus Biosciences, Inc.是一家临床阶段的生物制药公司，专注于在美国开发和商业化癌症疗法。该公司的管线产品包括 Domvanalimab，一种抗 TIGIT 抗体，目前处于第二阶段和第三阶段临床试验；以及 AB308，一种正在研究的抗 TIGIT 单克隆抗体，目前处于第一阶段 b 临床试验，旨在研究晚期实体瘤和血液恶性肿瘤患者。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票超过 Arcus Biosciences</li>
<li>卖空 - 利与弊</li>
<li>博通股票暴跌 20%——但华尔街认为其将飙升至 500 美元</li>
<li>如何在 7 个步骤中投资大麻股票</li>
<li>忘掉芯片：AI 反弹的 4 个工业投资机会</li>
<li>TSX 风险投资交易所（前身为加拿大风险投资交易所）</li>
<li>MongoDB 可能创下新高——但您需要迅速行动</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVJDVVM?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVJDVVM"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Arcus Biosciences 吗？</h2>
<p>在你考虑 Arcus Biosciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Arcus Biosciences 并不在名单上。</p>
<p>虽然 Arcus Biosciences 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

RCUS

<p>Richard Markus，Arcus Biosciences 的内部人士，以每股 21.88 美元的价格出售了 5,052 股公司股票，总计 110,537.76 美元。这笔交易使他的持股减少了 6.72%，剩余 70,141 股，价值 1,534,685.08 美元。该交易已在向美国证券交易委员会（SEC）的法律文件中披露。此外，Markus 在第二天以每股 22.16 美元的价格出售了 4,494 股。Arcus Biosciences 的股票目前交易价格为 22.02 美元，市值为 23.8 亿美元</p>

<p>Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) insider Richard Markus sold 5,052 shares of the business's stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $21.88, for a total value of $110,537.76. Following the sale, the insider owned 70,141 shares of the company's stock, valued at approximately $1,534,685.08. The trade was a 6.72% decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through this link.</p>
<div class="lb-trans"><p>Arcus Biosciences, Inc.（纽约证券交易所代码：RCUS - 获取免费报告）内部人士 Richard Markus 于 12 月 16 日（星期二）出售了 5,052 股该公司的股票。股票的平均售价为 21.88 美元，总价值为 110,537.76 美元。出售后，该内部人士持有 70,141 股公司的股票，价值约为 1,534,685.08 美元。此次交易使其持股减少了 6.72%。该交易已在与证券交易委员会的法律文件中披露，您可以通过此链接访问。</p>
</div><p>Get <strong>Arcus Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Arcus Biosciences</strong> 的提醒：</p>
</div><ul>
<li>From laggards to leaders: Small caps on the rise</li>
</ul>
<div class="lb-trans"><ul>
<li>从落后者到领导者：小型股正在崛起</li>
</ul>
</div><p>Richard Markus also recently made the following trade(s):</p>
<div class="lb-trans"><p>Richard Markus 最近还进行了以下交易：</p>
</div><ul>
<li>On Wednesday, December 17th, Richard Markus sold 4,494 shares of Arcus Biosciences stock. The shares were sold at an average price of $22.16, for a total value of $99,587.04.</li>
</ul>
<div class="lb-trans"><ul>
<li>在 12 月 17 日（星期三），Richard Markus 出售了 4,494 股 Arcus Biosciences 的股票。这些股票的平均售价为 22.16 美元，总价值为 99,587.04 美元。</li>
</ul>
</div><h2>Arcus Biosciences Trading Down 1.2%</h2>
<div class="lb-trans"><h2>Arcus Biosciences 股价下跌 1.2%</h2>
</div><p>Shares of NYSE RCUS traded down $0.26 during mid-day trading on Thursday, hitting $22.02. The company's stock had a trading volume of 1,175,874 shares, compared to its average volume of 1,200,446. Arcus Biosciences, Inc. has a one year low of $6.50 and a one year high of $26.40. The company's fifty day simple moving average is $20.82 and its 200-day simple moving average is $13.98. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.65 and a quick ratio of 3.65. The stock has a market cap of $2.38 billion, a price-to-earnings ratio of -6.40 and a beta of 0.75.</p>
<div class="lb-trans"><p>在周四的午盘交易中，纽约证券交易所 RCUS 的股票下跌了 0.26 美元，跌至 22.02 美元。该公司的股票交易量为 1,175,874 股，而其平均交易量为 1,200,446 股。Arcus Biosciences, Inc.的股价一年低点为 6.50 美元，一年高点为 26.40 美元。该公司的 50 日简单移动平均线为 20.82 美元，200 日简单移动平均线为 13.98 美元。该公司的债务与股本比率为 0.22，流动比率为 3.65，速动比率为 3.65。该股票的市值为 23.8 亿美元，市盈率为-6.40，贝塔值为 0.75。</p>
</div><ul>
<li>MarketBeat Week in Review – 7/10 - 7/14</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周报 – 7/10 - 7/14</li>
</ul>
</div><p>Arcus Biosciences (NYSE:RCUS - Get Free Report) last issued its earnings results on Tuesday, October 28th. The company reported ($1.27) EPS for the quarter, beating the consensus estimate of ($1.33) by $0.06. The company had revenue of $26.00 million during the quarter, compared to analysts' expectations of $19.89 million. Arcus Biosciences had a negative net margin of 136.40% and a negative return on equity of 68.17%. The business's revenue for the quarter was down 45.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.00) EPS. On average, sell-side analysts anticipate that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Arcus Biosciences（纽约证券交易所代码：RCUS - 获取免费报告）最近在 10 月 28 日（星期二）发布了其财报。该公司报告本季度每股收益（EPS）为-1.27 美元，超出市场共识预期的-1.33 美元 0.06 美元。该公司本季度的收入为 2600 万美元，而分析师预期为 1989 万美元。Arcus Biosciences 的净利润率为-136.40%，股本回报率为-68.17%。与去年同期相比，该公司的季度收入下降了 45.8%。在去年同期，该公司每股收益为-1.00 美元。平均而言，卖方分析师预计 Arcus Biosciences, Inc.在当前财年将发布-3.15 的每股收益。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several institutional investors have recently modified their holdings of RCUS. Amalgamated Bank increased its position in Arcus Biosciences by 3.9% during the third quarter. Amalgamated Bank now owns 19,533 shares of the company's stock worth $266,000 after buying an additional 736 shares during the last quarter. Creative Planning lifted its position in shares of Arcus Biosciences by 2.7% in the third quarter. Creative Planning now owns 29,629 shares of the company's stock valued at $403,000 after buying an additional 771 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Arcus Biosciences by 59.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,748 shares of the company's stock worth $37,000 after acquiring an additional 1,021 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its holdings in shares of Arcus Biosciences by 8.0% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 17,398 shares of the company's stock worth $142,000 after acquiring an additional 1,294 shares during the last quarter. Finally, Parallel Advisors LLC raised its stake in Arcus Biosciences by 1.6% in the 2nd quarter. Parallel Advisors LLC now owns 88,007 shares of the company's stock valued at $716,000 after acquiring an additional 1,422 shares during the period. 92.89% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>几家机构投资者最近调整了对 RCUS 的持股。Amalgamated Bank 在第三季度将其在 Arcus Biosciences 的持股增加了 3.9%。Amalgamated Bank 目前持有 19,533 股该公司的股票，价值 266,000 美元，此前在上个季度又购买了 736 股。Creative Planning 在第三季度将其在 Arcus Biosciences 的持股增加了 2.7%。Creative Planning 目前持有 29,629 股该公司的股票，价值 403,000 美元，此前在上个季度又购买了 771 股。GAMMA Investing LLC 在第三季度将其在 Arcus Biosciences 的持股增加了 59.1%。GAMMA Investing LLC 目前持有 2,748 股该公司的股票，价值 37,000 美元，此前在此期间又收购了 1,021 股。宾夕法尼亚州公共学校雇员退休系统在第二季度将其在 Arcus Biosciences 的持股增加了 8.0%。宾夕法尼亚州公共学校雇员退休系统目前持有 17,398 股该公司的股票，价值 142,000 美元，此前在上个季度又收购了 1,294 股。最后，Parallel Advisors LLC 在第二季度将其在 Arcus Biosciences 的持股增加了 1.6%。Parallel Advisors LLC 目前持有 88,007 股该公司的股票，价值 716,000 美元，此前在此期间又收购了 1,422 股。92.89% 的股票目前由机构投资者和对冲基金持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus</li>
</ul>
<div class="lb-trans"><ul>
<li>Gilead 通过在 AlloVir 和 Arcus 的投资扩大生物科技足迹</li>
</ul>
</div><p>Several brokerages have recently issued reports on RCUS. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Arcus Biosciences in a research report on Wednesday, October 8th. Wall Street Zen upgraded Arcus Biosciences from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Sunday. Wedbush set a $35.00 price objective on Arcus Biosciences and gave the stock an &#34;outperform&#34; rating in a research report on Wednesday, October 29th. UBS Group reissued a &#34;buy&#34; rating on shares of Arcus Biosciences in a research report on Monday. Finally, Citigroup reaffirmed a &#34;buy&#34; rating on shares of Arcus Biosciences in a research report on Friday, December 12th. Eight investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $28.89.</p>
<div class="lb-trans"><p>几家券商最近对 RCUS 发布了报告。Weiss Ratings 在 10 月 8 日（星期三）的研究报告中重新发布了对 Arcus Biosciences 股票的 “卖出（d-）” 评级。Wall Street Zen 在周日将 Arcus Biosciences 的评级从 “卖出” 上调至 “持有”。Wedbush 在 10 月 29 日（星期三）的研究报告中对 Arcus Biosciences 设定了 35.00 美元的目标价，并给予该股票 “跑赢大盘” 的评级。瑞银集团在周一的研究报告中重新发布了对 Arcus Biosciences 股票的 “买入” 评级。最后，花旗集团在 12 月 12 日（星期五）的研究报告中重申了对 Arcus Biosciences 股票的 “买入” 评级。八位投资分析师对该股票给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat，该股票目前的共识评级为 “适度买入”，共识目标价为 28.89 美元。</p>
</div><p><strong>Get Our Latest Research Report on RCUS</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 RCUS 研究报告</strong></p>
</div><h2>Arcus Biosciences Company Profile</h2>
<div class="lb-trans"><h2>Arcus Biosciences 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.</p>
<div class="lb-trans"><p>Arcus Biosciences, Inc.是一家临床阶段的生物制药公司，专注于在美国开发和商业化癌症疗法。该公司的管线产品包括 Domvanalimab，一种抗 TIGIT 抗体，目前处于第二阶段和第三阶段临床试验；以及 AB308，一种正在研究的抗 TIGIT 单克隆抗体，目前处于第一阶段 b 临床试验，旨在研究晚期实体瘤和血液恶性肿瘤患者。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Arcus Biosciences</li>
<li>Short Selling - The Pros and Cons</li>
<li>Broadcom Stock Crashes 20%—But Wall Street Sees It Soaring to $500</li>
<li>How to invest in marijuana stocks in 7 steps</li>
<li>Forget the Chips: 4 Industrial Plays for the AI Rebound</li>
<li>TSX Venture Exchange (Formerly Canadian Venture Exchange)</li>
<li>MongoDB Could Hit Record Highs—But You’ll Need to Move Fast</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Arcus Biosciences</li>
<li>卖空 - 利与弊</li>
<li>博通股票暴跌 20%——但华尔街认为其将飙升至 500 美元</li>
<li>如何在 7 个步骤中投资大麻股票</li>
<li>忘掉芯片：AI 反弹的 4 个工业投资机会</li>
<li>TSX 风险投资交易所（前身为加拿大风险投资交易所）</li>
<li>MongoDB 可能创下新高——但您需要迅速行动</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVJDVVM" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NYSE&amp;Symbol=RCUS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Arcus Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Arcus Biosciences 吗？</h2>
</div><p>Before you consider Arcus Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Arcus Biosciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcus Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Arcus Biosciences 并不在名单上。</p>
</div><p>While Arcus Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Arcus Biosciences 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

理查德·马库斯出售了 5,052 股 Arcus Biosciences（纽约证券交易所代码：RCUS）的股票